Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering
19 mars 2012 14h59 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Mar 19, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced that it has entered into definitive...
Marina Biotech and ProNAi Therapeutics Announce License Agreement for the Development of DNAi-Based Therapeutics
14 mars 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA and ANN ARBOR, MI--(Marketwire - Mar 14, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, and ProNAi Therapeutics, Inc....
Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in Tokyo
29 févr. 2012 07h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Feb 29, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today reported data demonstrating the continued...
Marina Biotech Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery Platform
22 févr. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Feb 22, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and...
Marina Biotech Announces Closure of Cambridge Site and Consolidation of R&D Operations in Bothell, WA
14 févr. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Feb 14, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closure of its Cambridge site...
Marina Biotech Announces Closing of $1.5 MM Bridge Loan
10 févr. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Feb 10, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closing of a bridge loan...
Marina Biotech Begins Trading on the OTCQX Tier of OTC Market
01 févr. 2012 19h53 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Feb 1, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's common stock...
Marina Biotech Starts Cohort 2 of Its Phase 1b START-FAP Clinical Trial of CEQ508
25 janv. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Jan 25, 2012) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that Cohort 2 in the Dose...
Marina Biotech Receives Notice of Acceptance for Patent Broadly Covering Its Unlocked Nucleobase Analog (UNA) Technology
23 janv. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Jan 23, 2012) - Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company today announced that the Intellectual Property...
Marina Biotech, Inc. Provides Update on Its Broad Nucleic Acid-Based Drug Discovery Platform and 2012 Goals
10 janv. 2012 06h30 HE
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Jan 10, 2012) - Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company, will provide an update on its nucleic...